3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Not yet recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Carcinoma, Non-Small-Cell Lung
19
Carcinoma, Hepatocellular
18
Stomach Neoplasms
17
Nasopharyngeal Carcinoma
15
Triple Negative Breast Neoplasms
13
Esophageal Squamous Cell Carcinoma
13
Breast Neoplasms
12
Squamous Cell Carcinoma of Head and Neck
11
Esophageal Neoplasms
11
Uterine Cervical Neoplasms
10
Colorectal Neoplasms
10
Sarcoma
9
Melanoma
6
Recurrence
5
Neoplasm Metastasis
5
Lung Neoplasms
5
Hodgkin Disease
5
Cholangiocarcinoma
5
Small Cell Lung Carcinoma
4
Pancreatic Neoplasms
4
Osteosarcoma
4
Parkinson Disease 4, Autosomal Dominant Lewy Body
3
Liver Neoplasms
3
Glioblastoma
3
Gestational Trophoblastic Disease
3
Endometrial Neoplasms
3
Biliary Tract Neoplasms
3
Solid Tumor
2
Rectal Neoplasms
2
NSCLC
2
Interventions
lenvatinib
1
camrelizumab
1
130-nm albumin-bound paclitaxel
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Advanced Triple Negative Breast Cancer
×
camrelizumab
×
Clear all
NCT06849492
2025-02-27
SHIFT-001
Fudan University
Phase 2
Not yet recruiting
120 enrolled